Source: Interfolio F180
Hugh Rosen, MD, PhD
Research Focus
Dr. Rosen, is Professor at Scripps Research Institute in La Jolla, California since 2002 and Chair of Molecular and Cellular Biology. He has focused on pursuing his primary interests in the chemical biology of immune regulation by signaling lipids and of receptor therapeutics. Fundamental mechanistic discoveries of the role of S1P receptors in immune trafficking and pathophysiology resulted in new insights immune mediated tissue damage and cytokine storm in both autoimmunity and viral infections. Tools discovered allowed the high-resolution crstallographic structure of the first lipid-binding GPCR. Chemical discovery, in collaboration with Professor Edward Roberts, led to the invention of ozanimod at Scripps Research. Ozanimod is now approved for the treatment of Multiple Sclerosis and Ulcerative Colitis and marketed by Bristol-Myers Squibb as ZEPOSIAR. Two further Scripps Research compounds from the Rosen & Roberts laboratories are in clinical trials; Navacaprant has started Phase 3 trials for Major Depressive Disorder and NMRA-511 has completed Phase 1 for anxiety disorders.
Education
MB.ChB. (Cape Town), D.Phil. (Oxford)Awards & Professional Activities
1990, Wellcome Senior Research Fellow in the Basic Biomedical Sciences, University of Oxford
1986, Junior Research Fellow in Medicine and Biological Sciences, Jesus College, Oxford
1983, Royal Commission for the Exhibition of 1851 Science Research Scholarship
1995, Fellow, Infectious Diseases Society of America
2013, Member, Henry Kunkel Society
2011, Fellow, American Academy of Microbiology
2008, Member, American Association of Physicians
2006-14: Associate Editor of Molecular Pharmacology (ASPET)
2007-12: Editorial Board of J. Biol. Chem. (ASBMB)
1990-2000: Editorial Board, The Biochemical Journal
2005-2007: Chair, N.I.H. Molecular Libraries Screening Center Network Steering Committee
Selected Publications
Guerrero, M.; Urbano, M.; Kim, E. K.; Gamo, A. M.; Riley, S.; Abgaryan, L.; Leaf, N.; Van Orden, L. J.; Brown, S. J.; Xie, J. Y.; Porreca, F.; Cameron, Michael D.; Rosen, Hugh; Roberts, Edward Design and synthesis of a novel and selective kappa opioid receptor (KOR) antagonist (BTRX-335140). Journal of Medicinal Chemistry 2019, 62, 1761-1780.
[View]
Teijaro, John R.; Studer, S.; Leaf, N.; Kiosses, W. B.; Nguyen, N.; Matsuki, K.; Negishi, H.; Taniguchi, T.; Oldstone, Michael B.; Rosen, Hugh S1PR1-mediated IFNAR1 degradation modulates plasmacytoid dendritic cell interferon-alpha autoamplification. Proceedings of the National Academy of Sciences of the United States of America 2016, 113, 1351-1356.
[View]
Rosen, Hugh; Rosen, Hugh; Stevens, Raymond C.; Roberts, Edward; Roberts, Edward; Oldstone, Michael B.; Oldstone, Michael B.; Hanson, Michael A. Sphingosine-1-phosphate and its receptors: structure, signaling, and influence. Annual review of biochemistry 2013, 82, 637-62.
[View]
Hanson, Michael A.; Roth, Christopher B.; Jo, E. J.; Griffith, M. T.; Scott, F. L.; Reinhart, G.; Desale, H.; Clemons, B.; Cahalan, Stuart M.; Schuerer, S. C.; Sanna, M. G.; Han, G. W.; Kuhn, Peter A.; Rosen, Hugh; Stevens, Raymond C. Crystal structure of a lipid G protein-coupled receptor. Science 2012, 335, 851-855.
[View]
Cahalan, Stuart M.; Gonzalez-Cabrera, P. J.; Sarkisyan, G.; Nguyen, N.; Schaeffer, M. T.; Huang, L. M.; Yeager, A.; Clemons, B.; Scott, F.; Rosen, Hugh Actions of a picomolar short-acting S1P(1) agonist in S1P(1)-eGFP knock-in mice. Nature Chemical Biology 2011, 7, 254-256.
[View]
Mandala, Suzanne; Hajdu, Richard; Bergstrom, James; Quackenbush, Elizabeth; Xie, Jenny; Milligan, James; Thornton, Rosemary; Shei, Gan- J.; Card, Deborah; Keohane, CarolAnn; Rosenbach, Mark; Hale, Jeffrey; Lynch, Christopher L.; Rupprecht, Kathleen; Parsons, William; Rosen, Hugh Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. 2002, 296, 346-9.